Generic Drugs

Teva Investors Are Back on the Rollercoaster

27.09.18 | Lilach Baumer

Mylan Cuts Price of Generic Copaxone Offering by 60%

11.07.18 | Lilach Baumer

Teva Shut Down New York, Washington Offices, Says CEO

23.02.18 | Dror Reich

As Part of Cost-Cutting Plan, Teva Will Shut Down Twenty or More Manufacturing Sites

10.01.18 | Lilach Baumer

The Crucial Piece of Information Teva Overlooked

24.12.17 | Sophie Shulman

New CEO Steers Teva Back to Generics

28.11.17 | Golan Hazani and Dror Reich

Investors Cheer as Mylan Plans to Delist from Israeli Stock Exchange

12.11.17 | Uri Tal-Tenne and Dror Reich

Generic Dependence Threatens Teva’s Ability to Haul Debt Load

05.11.17 | Dror Reich and Lilach Baumer

New CEO to Take Helm at Troubled Teva Wednesday

31.10.17 | Lilach Baumer

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17 | Lilach Baumer

Cerberus, Advent Eye Teva's European Assets, Report Says

15.08.17 | Calcalist

With Bloated Debt, Teva Looks to Sell Assets

10.08.17 | Eli Shimony and Gil Kalian